ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2026
Surgical approach and oncological outcomes in Siewert type II junctional tumors.
Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal surgery for Siewert type II tumors remains controversial. We compared outcomes between transthoracic esophagectomy (TTE) and extended total gastrectomy (EG) in a high-volume center. This study included consecutive patients with Siewert type II tumors undergoing curative-intent surgery between 2013 and 2023. Patients treated with TTE or EG were analyzed. Primary outcomes were oncological parameters (lymph node yield, margin length, R0-rate, positive lymph nodes). Secondary outcomes included postoperative morbidity, overall survival (OS), disease-free survival (DFS), and recurrence patterns. Survival was analyzed using Kaplan-Meier and multivariable Cox regression. A total of 136 patients were included (TTE n = 71; EG n = 65). Baseline characteristics were largely comparable. TTE resulted in a significantly higher median lymph node yield (45 vs. 28, P < 0.001) and longer proximal margins (P < 0.001). R0 resection rates were similar (94.4% vs. 86.0%, P = 0.217), as was the number of positive lymph nodes. Clavien-Dindo ≥3b complications occurred in 38.0% vs. 38.5% (P = 1.000). Median OS was 2.9 years in both groups, with no difference in OS (log-rank P = 0.611) or DFS (log-rank P = 0.530). On multivariable analysis, surgical approach was not associated with OS (aHR 1.08, 95% CI 0.64-1.82), whereas advanced pathological stage (pT3-4) independently predicted worse survival (aHR 2.03, 95% CI 1.18-3.51). Despite differences in lymph node yield and proximal margin length, TTE and EG provide comparable oncological and survival outcomes in Siewert type II tumors. These results were sustained even after multivariate adjustment. These findings support an individualized, multidisciplinary approach to surgical strategy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.